MZB1 and ovarian carcinoma: The results suggest that both peripheral blood markers and TICs can be used as prognostic predictors in patients with ovarian cancer, and CXCL9, CD79A, MS4A1, and MZB1 may be potential therapeutic targets for ovarian cancer immunotherapy.